港股异动 | 三生制药(01530)升6% 特比澳新增儿童ITP适应症上市申请获受理

智通财经2022-11-10

智通财经APP获悉，三生制药(01530)再度活跃，午后升约6%。公司核心产品特比澳新上市申请日前获NMPA受理，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症（ITP）。今年上半年，特比澳在公司收入中占比达50.95%。截至发稿，三生制药涨5.65%，报6.73港元，成交额1.52亿港元。11月9日，三生制药宣布，公司向NMPA提交的重组人血小板生成素注射液（特比澳）新上市申请已于日前...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2282575061?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-11-10 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2282575061","market":"sh","top_or_hot":-1,"title":"港股异动 | 三生制药(01530)升6% 特比澳新增儿童ITP适应症上市申请获受理","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，三生制药(01530)再度活跃，午后升约6%。公司核心产品特比澳新上市申请日前获NMPA受理，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症（ITP）。今年上半年，特比澳在公司收入中占比达50.95%。截至发稿，三生制药涨5.65%，报6.73港元，成交额1.52亿港元。11月9日，三生制药宣布，公司向NMPA提交的重组人血小板生成素注射液（特比澳）新上市申请已于日前...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/827905.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 三生制药(01530)升6% 特比澳新增儿童ITP适应症上市申请获受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 三生制药(01530)升6% 特比澳新增儿童ITP适应症上市申请获受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-10 14:28 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/827905.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，三生制药(01530)再度活跃，午后升约6%。公司核心产品特比澳新上市申请日前获NMPA受理，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症（ITP）。今年上半年，特比澳在公司收入中占比达50.95%。截至发稿，三生制药涨5.65%，报6.73港元，成交额1.52亿港元。11月9日，三生制药宣布，公司向NMPA提交的重组人血小板生成素注射液（特比澳）新上市申请已于日前...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/827905.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/827905.html","article_id":"2282575061","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2282575061","pubTimestamp":1668061688,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，三生制药再度活跃，午后升约6%。截至发稿，三生制药涨5.65%，报6.73港元，成交额1.52亿港元。11月9日，三生制药宣布，公司向NMPA提交的重组人血小板生成素注射液（特比澳）新上市申请已于日前获得受理，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症。特比澳作为三生制药自主研发的全球唯一商业化的重组人血小板生成素产品，2005年产品成功上市。今年上半年，特比澳实现销售15.75亿元，在公司收入中占比达50.95%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","BK4199":"纸制品","01530":"三生制药","ITP":"IT科技包装","BK1161":"生物科技","BK1593":"医美概念股"},"translate_title":"Hong Kong stocks changed Sansheng Pharmaceutical (01530) rose by 6%. The application for listing of new children's ITP indications in Tebi'ao was accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1,"ITP":1,"SSRX":1},"content_text":"智通财经APP获悉，三生制药(01530)再度活跃，午后升约6%。公司核心产品特比澳新上市申请日前获NMPA受理，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症（ITP）。今年上半年，特比澳在公司收入中占比达50.95%。截至发稿，三生制药涨5.65%，报6.73港元，成交额1.52亿港元。11月9日，三生制药宣布，公司向NMPA提交的重组人血小板生成素注射液（特比澳）新上市申请已于日前获得受理，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症（ITP）。特比澳作为三生制药自主研发的全球唯一商业化的重组人血小板生成素(rhTPO)产品，2005年产品成功上市。今年上半年，特比澳实现销售15.75亿元，在公司收入中占比达50.95%。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2282575061"}